Only liraglutide (saxenda) and semaglutide (wegovy) are indicated for obesity. Originally developed for type 2 diabetes, these medications mimic a hormone naturally produced in your intestines that regulates appetite and blood sugar. ‘the australian health system is an important test bed for how to strike a balance between addressing obesity‐related health concerns, while maintaining the financial sustainability of healthcare systems given the uncertain health economics of.
Dr gary deed, chair of racgp specific interests diabetes, said the ‘promising results’ add further evidence for the use of semaglutide as an adjunct to clinical weight management, especially in those overweight and obese people.